Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...4849505152535455565758...5960»
  • ||||||||||  Clinical, Journal:  An uncommon cause of acute abdomen in an acromegalic patient: colonic volvulus. (Pubmed Central) -  Aug 23, 2019   
    The occurrence of volvulus including the whole colon, although the pituitary adenoma was treated and partial colectomy was done, refers to predisposing factor being the irreversible effect of acromegaly on the colon. KEY WORDS: Acromegaly, Emergency, Volvulus.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly (clinicaltrials.gov) -  Aug 21, 2019   
    P=N/A,  N=16, Completed, 
    KEY WORDS: Acromegaly, Emergency, Volvulus. Recruiting --> Completed | Trial completion date: Dec 2016 --> Mar 2019 | Trial primary completion date: Dec 2016 --> Mar 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  Acromegaly & Sleep Apnoea (clinicaltrials.gov) -  Aug 19, 2019   
    P=N/A,  N=653, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2016 --> Mar 2019 | Trial primary completion date: Dec 2016 --> Mar 2019 Recruiting --> Completed | N=1000 --> 653
  • ||||||||||  Clinical, Review, Journal:  Insulin Resistance in Patients With Acromegaly. (Pubmed Central) -  Aug 17, 2019   
    In addition, we highlight the role of insulin resistance in the development of acromegaly-associated complications such as hypertension, cardiac disease, sleep apnea, polycystic ovaries, bone disease, and cancer. Taken together, insulin resistance is an important metabolic hallmark of acromegaly, which is strongly related to disease activity, the development of comorbidities, and might even impact the response to drugs used in the treatment of acromegaly.
  • ||||||||||  Journal:  Growth Hormone's Links to Cancer. (Pubmed Central) -  Aug 17, 2019   
    Replacement GH therapy in GHD hypopituitary adults and short children has been shown to be safe when no other risk factors for malignancy are present. Nevertheless, the use of GH in cancer survivors and in short children with RASopathies, chromosomal breakage syndromes or DNA-repair disorders should be carefully evaluated due to an increased risk of recurrence, primary cancer or second neoplasia in these individuals.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Clinical, Journal:  Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain. (Pubmed Central) -  Aug 16, 2019   
    After 5 years of treatment, the probability that pegvisomant generated savings versus pasireotide would be 65.3%. The favorable effects of pegvisomant on glucose metabolism would allow a considerable number of cases of DM to be avoided compared to pasireotide, resulting in savings for the NHS in Spain.
  • ||||||||||  Enrollment open:  Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (clinicaltrials.gov) -  Aug 14, 2019   
    P=N/A,  N=30, Recruiting, 
    Mechanisms regulating ghrelin acylation and function of each form need elucidation in order to improve diagnostics and treatment of metabolic disturbances, not only acromegaly. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Mutations in GPR101 as a potential cause of X-linked acrogigantism and acromegaly. (Pubmed Central) -  Aug 11, 2019   
    Some GPR101 mutations that are associated with a small proportion of pituitary tumors without GH oversecretion have also been identified recently. This chapter will summarize studies on GPR101, including its molecular cloning and tissue distribution, physiology, pharmacology, and pathophysiology.
  • ||||||||||  Review, Journal:  The Endothelium in Acromegaly. (Pubmed Central) -  Aug 10, 2019   
    Preclinical markers of atherosclerosis as arterial intima media thickness, pulse wave velocity and flow mediated dilation seem to be impaired in acromegaly and partly mediated by the endothelium dysfunction. In conclusion, the pathophysiology of endothelial dysfunction in the condition of GH and IGF-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications.
  • ||||||||||  Journal:  The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas. (Pubmed Central) -  Aug 3, 2019   
    We concluded that SSA treatment appears to decrease Ki-67 proliferation index independent of tumor features, SSA type, dose and treatment duration. This result suggests that SSA treatment may decrease cellular proliferation, supporting the previous studies.
  • ||||||||||  Review, Journal:  Acromegaly and Heart Failure. (Pubmed Central) -  Jul 31, 2019   
    Control of acromegaly, induced by either pituitary surgery or medical therapy improves cardiac structure and performance, limiting the progression of acromegaly cardiomyopathy to CHF. However, when CHF is associated with dilative cardiomyopathy, it is generally not reversible, despite the treatment of the acromegaly.
  • ||||||||||  Clinical, Journal:  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. (Pubmed Central) -  Jul 24, 2019   
    The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients.
  • ||||||||||  Review, Journal:  A Consensus Statement on acromegaly therapeutic outcomes. (Pubmed Central) -  Jul 19, 2019   
    The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice.
  • ||||||||||  Clinical, Journal:  Acromegaly remission, SIADH and pituitary function recovery after macroadenoma apoplexy (Pubmed Central) -  Jul 18, 2019   
    We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice. For this reason, closely monitoring sodium at the beginning of the episode and throughout the first week is advisable to guard against SIADH.Despite being less frequent, if pituitary apoplexy is limited to the tumour, the patient can recover pituitary function previously damaged by the undiagnosed macroadenoma.
  • ||||||||||  Journal:  Growth hormone and chronic kidney disease. (Pubmed Central) -  Jul 17, 2019   
    Our understanding of the cellular and molecular effects of GH in the pathogenesis of renal complications of diabetes and acromegaly has significantly progressed in recent years. These observations open up new possibilities in the prevention and treatment of diabetic nephropathy.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  The real costs of acromegaly: analysis of different therapies. (Pubmed Central) -  Jul 13, 2019   
    Life-long treatment of acromegaly and its comorbidities is very expensive. Early diagnosis and successful treatment reduce direct and indirect costs.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Journal:  Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. (Pubmed Central) -  Jul 13, 2019   
    In every case, acromegaly sequelae require life-long monitoring and active treatment. Current recommendations, being an updated version of the recommendations published in Endokrynologia Polska in 2014, which take into account the Polish situation, should prove useful in the management of patients with acromegaly.
  • ||||||||||  Clinical, Journal:  Impact of transsphenoidal surgery on asymptomatic cardiomyopathy in patients with acromegaly. A single-blinded study. (Pubmed Central) -  Jul 13, 2019   
    Current recommendations, being an updated version of the recommendations published in Endokrynologia Polska in 2014, which take into account the Polish situation, should prove useful in the management of patients with acromegaly. Reduction in growth hormone levels and insulin-like growth factor type 1 can decrease the LVM and LVMI, which directly or indirectly contributes to the improvement in diastolic as well as systolic function and probably mortality.
  • ||||||||||  Review, Journal:  Colonic Cancer and Acromegaly. (Pubmed Central) -  Jul 12, 2019   
    Furthermore, an increased lifetime risk of malignant transformation of pre-malignant colonic lesions relates to a worse overall prognosis from colorectal cancer, which is currently considered a major disease-related complication. In this review we provide some insight into colonic changes in this condition, summarize current knowledge and evidence on the use of colonoscopic screening in patients with acromegaly, and suggest a recommended screening protocol.
  • ||||||||||  Review, Journal:  Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies. (Pubmed Central) -  Jun 28, 2019   
    Several emerging, novel, medical treatments for acromegaly, Cushing's disease and prolactinomas are in phase II and III clinical trials and may become effective additions to the current drug armamentarium. The availability of various management options will allow an individualised treatment approach based on the unique tumour type, clinical situation and patient preference.